Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI

Autor: Delor I, Charoin Je, Sylvie Retout, Jacqmin P, Ronald Gieschke

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

Alzheimer's disease (AD), the most common dementing illness in the elderly, is a major growing public health issue as life expectancy increases. AD is characterized by a slow decline in cognitive and functional ability assessed by various clinical, b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b00647428ed154c445c16284010ac636
https://doi.org/10.1038/psp.2013.54

Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.

Autor: Nishimura JI; Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan., Soubret A; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Arase N; Department of Dermatology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan., Buatois S; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Hotta M; Department of Medical Technology, Osaka University Hospital, Osaka, Japan., Charoin JE; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Ito Y; Department of Hematology, Tokyo Medical University Hospital, Tokyo, Japan., Sreckovic S; Genentech, Inc., South San Francisco, California, USA., Takamori H; Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan., Bucher C; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Ueda Y; Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan., Hernández-Sánchez J; F. Hoffmann-La Roche Ltd., Basel, Switzerland., Gotanda K; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Jordan G; Roche Pharma Research and Early Development, Roche Innovation Center Munich, Munich, Germany., Shinomiya K; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Ramos J; Genentech, Inc., South San Francisco, California, USA.; Spark Therapeutics, Inc., Philadelphia, Pennsylvania, USA., Kim JS; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea., Panse J; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany., de Latour RP; Hematology and Bone Marrow Transplant Department, Saint-Louis Hospital, Paris, France., Röth A; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Morii E; Department of Pathology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan., Schrezenmeier H; Institute of Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen und University Hospital Ulm, Ulm, Germany., Isaka Y; Department of Nephrology, Graduate School of Medicine, Faculty of Medicine, Osaka, Japan., Sica S; Fondazione Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy., Kanakura Y; Department of Hematology and Oncology, Graduate School of Medicine, Faculty of Medicine, Osaka University, Osaka, Japan.; Department of Hematology, Sumitomo Hospital, Osaka, Japan., Yoon SS; Seoul National University Hospital, Seoul, Korea., Kinoshita T; Yabumoto Department of Intractable Disease Research, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan., Paz-Priel I; Genentech, Inc., South San Francisco, California, USA.; Gilead Sciences, San Francisco, California, USA., Sostelly A; Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.; Alnylam Pharmaceuticals, Basel, Switzerland.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2023 Apr; Vol. 113 (4), pp. 904-915. Date of Electronic Publication: 2023 Feb 12.

Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B.

Autor: Feng S; Pharmaceutical Sciences, Roche Innovation Center Shanghai, Shanghai, China., Bo Q; I2O DTA, Roche Innovation Center Shanghai, Shanghai, China., Coleman HA; Covance, Daytona Beach, Florida, USA., Charoin JE; Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland., Zhu M; I2O DTA, Roche Innovation Center Shanghai, Shanghai, China., Xiao J; Frontage Laboratories, Exton, Pennsylvania, USA., Jin Y; Pharmaceutical Sciences, Roche Innovation Center Shanghai, Shanghai, China.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Aug; Vol. 61 (8), pp. 1027-1034. Date of Electronic Publication: 2021 Apr 21.

Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer Immunotherapy.

Autor: Ribba B; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland. benjamin.ribba@roche.com., Boetsch C; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland., Nayak T; Translational Imaging Science Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland., Grimm HP; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland., Charo J; Translational Medicine Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland., Evers S; Translational Medicine Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland., Klein C; Discovery Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland., Tessier J; Translational Imaging Science Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland., Charoin JE; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Basel, Switzerland., Phipps A; Pharmaceutical Sciences, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Welwyn, England., Pisa P; Translational Medicine Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland., Teichgräber V; Translational Medicine Oncology, Roche Pharmaceutical Research & Early Development, Roche Innovation Center, Zurich, Switzerland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Jul 15; Vol. 24 (14), pp. 3325-3333. Date of Electronic Publication: 2018 Feb 20.

Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.

Autor: Chanu P; PharmD, Pharsight - A Certara Company, Lyon, France. chanu.pascal@wanadoo.fr, Gieschke R, Charoin JE, Pannier A, Reigner B

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2010 May; Vol. 50 (5), pp. 507-20. Date of Electronic Publication: 2010 Feb 23.